ACIU vs ADXN
AC Immune SA and Addex Therapeutics Ltd., side by side — 7 fiscal years reported in CHF, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ACIU | ADXN |
|---|---|---|
| Revenue | CHF 3.6M | CHF 404,102 |
| Net income | CHF -70.4M | CHF 7.1M |
| Gross margin | — | — |
| Net margin | −1971.6% | 1746.0% |
| Return on equity | — | — |
| Diluted EPS | −CHF 0.70 | CHF 0.07 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | CHF -70.2M | CHF -5.4M |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 1.02× | 4.42× |
| Revenue CAGR 5y | −25.4% | −31.9% |
| Profit CAGR 5y | — | — |
ACIU bills 8.8× the revenue of ADXN, and ACIU closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | ACIU | ADXN |
|---|---|---|
| FY2024 | CHF 27.3M | CHF 404,102 |
| FY2023 | CHF 14.8M | CHF 1.6M |
| FY2022 | CHF 3.9M | CHF 1.4M |
| FY2021 | CHF 0 | CHF 2.9M |
| FY2020 | CHF 15.4M | CHF 3.6M |
| FY2019 | CHF 110.5M | CHF 2.8M |
| FY2018 | CHF 6.9M | CHF 6.0M |
Net income by year
Bottom line
| Fiscal year | ACIU | ADXN |
|---|---|---|
| FY2024 | CHF -50.9M | CHF 7.1M |
| FY2023 | CHF -54.2M | CHF -10.6M |
| FY2022 | CHF -70.8M | CHF -20.8M |
| FY2021 | CHF -73.0M | CHF -15.4M |
| FY2020 | CHF -61.9M | CHF -12.9M |
| FY2019 | CHF 45.4M | CHF -14.8M |
| FY2018 | CHF -51.0M | CHF -1.6M |
Advertisement
AdSense · Rectangle 336×280